BKM Wealth Management LLC Raises Position in Zoetis Inc. (NYSE:ZTS)

BKM Wealth Management LLC increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 57.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,809 shares of the company’s stock after purchasing an additional 2,845 shares during the period. BKM Wealth Management LLC’s holdings in Zoetis were worth $1,526,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Webster Bank N. A. raised its stake in shares of Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after buying an additional 82 shares in the last quarter. Quarry LP lifted its holdings in Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after acquiring an additional 153 shares during the period. LRI Investments LLC purchased a new stake in shares of Zoetis during the 1st quarter worth $43,000. Central Valley Advisors LLC acquired a new position in shares of Zoetis during the 2nd quarter worth $49,000. Finally, Future Financial Wealth Managment LLC purchased a new position in Zoetis in the 3rd quarter valued at approximately $59,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Piper Sandler lifted their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. BTIG Research increased their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Stifel Nicolaus raised their target price on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, JPMorgan Chase & Co. increased their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Zoetis has a consensus rating of “Buy” and an average target price of $221.44.

Zoetis Stock Down 0.8 %

NYSE:ZTS opened at $180.01 on Friday. The business’s fifty day moving average price is $189.18 and its 200 day moving average price is $177.61. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The firm has a market capitalization of $82.14 billion, a price-to-earnings ratio of 34.68, a PEG ratio of 2.94 and a beta of 0.89. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.07. The company had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business’s revenue was up 8.3% compared to the same quarter last year. During the same period last year, the company earned $1.41 earnings per share. On average, sell-side analysts forecast that Zoetis Inc. will post 5.83 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be paid a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 0.96%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s payout ratio is currently 33.14%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.